The biotech firm’s quarterly loss exceeded analyst estimates by $0.02, signaling higher-than-anticipated costs.
Taysha Gene Therapies reported a GAAP loss of $0.12 per share for the quarter, missing expectations by $0.02. The wider loss reflects increased research and development expenses as the company advances its gene therapy pipeline.
Analysts had anticipated a loss of $0.10 per share, based on prior guidance and industry benchmarks. The company’s cash burn rate has accelerated as it scales clinical trials for rare genetic disorders.
Shares showed limited movement in after-hours trading, reflecting investor focus on long-term pipeline potential over near-term financials.